Chauvin v. Bayer Healthcare Pharmaceuticals, Inc.
- John Tunheim
- 0:18-cv-00579
- U.S. District Court · District of Minnesota
- 6
In Chauvin v. Bayer HealthCare Pharmaceuticals Inc., Judge Tunheim dismissed the Chauvins’ case with prejudice for failing to retain required experts.
Barbara and Mark Chauvin, whose product-liability case against Bayer HealthCare Pharmaceuticals Inc. was dismissed with prejudice.
What happened
Barbara and Mark Chauvin pursued a product-liability case against Bayer HealthCare Pharmaceuticals Inc. after choosing not to participate in a voluntary settlement program. A court order required them to retain experts on general causation and Bayer’s liability, and the court gave them multiple extensions to comply.
The Chauvins argued that letters they sent to potential experts satisfied the requirement and that Bayer had given up its right to challenge expert testimony. The court found that the letters did not show the experts had agreed to serve or would be available for required proceedings, and concluded that Bayer had preserved its right to renew its challenge.
The court found that the Chauvins had not shown why their case should remain pending and dismissed the case with prejudice. Chief Judge John R. Tunheim entered judgment accordingly.
The detailed version
- Chauvin v. Bayer Healthcare Pharmaceuticals, Inc. · No. 0:18-cv-00579
- John Tunheim
- Oct. 6, 2020
Background
Barbara and Mark Chauvin were plaintiffs in multidistrict litigation involving fluoroquinolone products. They chose not to participate in a voluntary settlement program and therefore became “Litigating Plaintiffs.” Pre-Trial Order 18 required those plaintiffs to provide specified information and documents, including expert reports addressing general causation, case-specific causation, and the defendant’s liability. The order also required them to formally retain general-causation and liability experts.
The court previously ordered the Chauvins to show cause—meaning to explain why their case should not be dismissed—and granted them a 40-day extension. On April 6, 2020, the court granted another 90-day extension, which expired on July 6, 2020. The Chauvins filed a memorandum asserting that they had complied, but Bayer renewed its request for an order requiring them to show cause.
Arguments and analysis
The court concluded that the Chauvins had not retained the required experts. Letters they sent to experts associated with the plaintiffs’ leadership group did not establish that the experts had agreed to be retained or would be available for depositions and pretrial motion hearings. The letters were also sent after the 90-day extension had expired.
The Chauvins additionally argued that Bayer had waived its right to challenge expert testimony under the rule established in Daubert v. Merrell Dow Pharmaceuticals, Inc. The court rejected that argument, finding that Bayer had withdrawn an earlier challenge as part of the settlement agreement while preserving the right to renew the challenge against experts offered by Litigating Plaintiffs. The court also rejected the Chauvins’ request to transfer the case to the Eastern District of Louisiana, explaining that Pre-Trial Order 18 assigned related expert challenges to this court and provided that transfer would occur only when a case was ready for trial.
Ruling
The court held that Pre-Trial Order 18 and the April 6 order required the Chauvins to retain general-causation and liability experts, and that they had not done so despite multiple orders and extensions. The court found that they had not shown cause why the case should remain pending and dismissed Plaintiff’s case with prejudice. Chief Judge John R. Tunheim ordered that judgment be entered accordingly.
Read the full 6-page opinion on CourtListener, the free public archive maintained by the Free Law Project.